ACTIVE SINCE: Since 2020

BLINCYTO paediatric humanitarian access program

In specific hospitals aligned with the St Jude Children's Research Hospital global network, qualifying pediatric patients with B-cell precursor Acute Lymphoblastic Leukemia (ALL) can apply for access to BLINCYTO (blinatumomab) through their treating physician.
Funding and technical support; provision of medicines. Provision of training
Global NGOs 1

The Blincyto (blinatumomab) Humanitarian Access program was created to provide access to Blincyto for pediatric patients with B-cell precursor Acute Lymphoblastic Leukemia (ALL) living in low- to middle-income countries where Blincyto is not commercially available (and where there are very limited treatment options).

Amgen partners with St. Jude Children’s Research Hospital (a global leader in pediatric cancer care) and Direct Relief (a non-profit organization well known for its logistics capabilities in LMICs) to implement the program. Carefully selected and qualified hospitals receive Blincyto for qualifying patients, together with training and ongoing support to ensure safe administration and patient care. The medical training not only build the skills of the doctors and nurses to safely use Blincyto, but also the capabilities of hospitals in immunotherapy more generally.


Results and milestones

By January 2024, 130 children have been treated via the program in India and Pakistan.

Geographic Reach
  • Eastern Mediterranean
  • South-East Asia
  • Western Pacific
See Where
Disease Area
  • Non-communicable diseases
See Disease Areas
Target Population
  • Children
Partner organizations
Global NGOs

Technical expertise including logistics (securing import approvals, maintaining stock, and shipping product to treating physician).